Latest
Markets NEIMETH

Closing prices from 19 Oct 2026

Last refreshed Oct 19, 2026 17:00 WAT

NE

Neimeth International PharmaceuticalsNEIMETH

HEALTHCARE NGX
₦8.10 +₦0.45 (+5.88%)

closing price · trade date October 19, 2026

Ride this chart
Price
₦8.10
October 19, 2026
+5.88%

Key Trading Data

Latest imported Nigerian Exchange session data.

Open
₦7.65
Previous close
₦7.65
High
₦8.20
Low
₦8.05
Volume
2,765,501
Value traded
₦21,936,639.15
Trades
298
Market
Main Board
Currency
NGN

About Neimeth International Pharmaceuticals

Neimeth International Pharmaceuticals Plc is a Nigeria-based pharmaceutical manufacturer and marketer, specializing in therapeutic medicines, consumer healthcare, and veterinary products.

Neimeth International Pharmaceuticals Plc was incorporated in Nigeria in 1957 as Pfizer Products Plc, before transitioning to its current independent corporate identity. The company is a Nigerian pharmaceutical company serving mainly the domestic healthcare market, focused on the manufacturing, marketing, and distribution of pharmaceutical formulations and veterinary products.

The company's product portfolio spans various therapeutic segments, including anti-infectives, cardiovascular support, pain management, and nutritional supplements. Neimeth operates pharmaceutical manufacturing facilities in Nigeria subject to local regulatory oversight, primarily serving the domestic market.

Sector
Healthcare
Sub-Sector
Pharmaceuticals
Incorporation Year
1957
Headquarters
Lagos, Nigeria

Operations & Product Portfolio

Neimeth manufactures a diverse range of pharmaceutical formulations, including tablets, liquid orals, and topicals. Its notable brands cater to various healthcare needs, such as antiseptic care, deworming, and chronic disease management. The company maintains distribution networks across Nigeria to ensure product accessibility.

Industry Position & Growth Strategy

Operating within the competitive Nigerian healthcare sector, Neimeth focuses on expanding its local production capacity to reduce reliance on imported finished medicines. The company has disclosed plans or initiatives aimed at improving production capacity and regulatory compliance.

More

We use essential cookies for sign-in, security, and saving your competition session. Read our Privacy Policy.